Home Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration
Article
Licensed
Unlicensed Requires Authentication

Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration

  • Isobel A. Scarisbrick , Rachel Linbo , Alexander G. Vandell , Mark Keegan , Sachiko I. Blaber , Michael Blaber , Diane Sneve , Claudia F. Lucchinetti , Moses Rodriguez and Eleftherios P. Diamandis
Published/Copyright: May 15, 2008
Biological Chemistry
From the journal Volume 389 Issue 6

Abstract

Tissue kallikrein KLK1 and the kallikrein-related peptidases KLK2–15 are a subfamily of serine proteases that have defined or proposed roles in a range of central nervous system (CNS) and non-CNS pathologies. To further understand their potential activity in multiple sclerosis (MS), serum levels of KLK1, 6, 7, 8 and 10 were determined in 35 MS patients and 62 controls by quantitative fluorometric ELISA. Serum levels were then correlated with Expanded Disability Status Scale (EDSS) scores determined at the time of serological sampling or at last clinical follow-up. Serum levels of KLK1 and KLK6 were elevated in MS patients (p≤0.027), with highest levels associated with secondary progressive disease. Elevated KLK1 correlated with higher EDSS scores at the time of serum draw and KLK6 with future EDSS worsening in relapsing remitting patients (p≤0.007). Supporting the concept that KLK1 and KLK6 promote degenerative events associated with progressive MS, exposure of murine cortical neurons to either kallikrein promoted rapid neurite retraction and neuron loss. These novel findings suggest that KLK1 and KLK6 may serve as serological markers of progressive MS and contribute directly to the development of neurological disability by promoting axonal injury and neuron cell death.


Corresponding author

Received: 2007-11-30
Accepted: 2008-2-27
Published Online: 2008-05-15
Published in Print: 2008-06-01

©2008 by Walter de Gruyter Berlin New York

Articles in the same Issue

  1. Editorial
  2. Kallikreins and kallikrein-related peptidases
  3. Guest Editorial
  4. The 2nd International Symposium on Kallikreins and Kallikrein-Related Peptidases (ISK 2007) and the Commemorative Gold Medal of the E.K. Frey–E. Werle Foundation of the Henning L. Voigt Family
  5. Highlight: Kallikrein, kinins and kallikrein-related peptidases
  6. Structures and specificity of the human kallikrein-related peptidases KLK 4, 5, 6, and 7
  7. Development of peptides specifically modulating the activity of KLK2 and KLK3
  8. Kallikreins and proteinase-mediated signaling: proteinase-activated receptors (PARs) and the pathophysiology of inflammatory diseases and cancer
  9. Prostatic trypsin-like kallikrein-related peptidases (KLKs) and other prostate-expressed tryptic proteinases as regulators of signalling via proteinase-activated receptors (PARs)
  10. Human tissue kallikreins as promiscuous modulators of homeostatic skin barrier functions
  11. A potential role for tissue kallikrein-related peptidases in human cervico-vaginal physiology
  12. microRNAs: a new frontier in kallikrein research
  13. Functions of KLK4 and MMP-20 in dental enamel formation
  14. Genetic deficiency in tissue kallikrein activity in mouse and man: effect on arteries, heart and kidney
  15. Development of diabetic cardiomyopathy and the kallikrein-kinin system – new insights from B1 and B2 receptor signaling
  16. Doxorubicin cardiomyopathy-induced inflammation and apoptosis are attenuated by gene deletion of the kinin B1 receptor
  17. Attenuation of left ventricular dysfunction by an ACE inhibitor after myocardial infarction in a kininogen-deficient rat model
  18. Tissue kallikrein and kinin infusion promotes neovascularization in limb ischemia
  19. Kallikreins as microRNA targets: an in silico and experimental-based analysis
  20. Kallikreins are associated with secondary progressive multiple sclerosis and promote neurodegeneration
  21. Immunofluorometric activity-based probe analysis of active KLK6 in biological fluids
  22. Kallikrein 6 is a mediator of K-RAS-dependent migration of colon carcinoma cells
  23. Gene expression changes associated with the anti-angiogenic activity of kallikrein-related peptidase 3 (KLK3) on human umbilical vein endothelial cells
  24. An AKT activity threshold regulates androgen-dependent and androgen-independent PSA expression in prostate cancer cell lines
  25. Quantitative RT-PCR analysis and immunohistochemical localization of the kallikrein-related peptidases 13 and 14 in lung
Downloaded on 19.9.2025 from https://www.degruyterbrill.com/document/doi/10.1515/BC.2008.085/html
Scroll to top button